Redeye: A good BET in Nuevolution
Nuevolution has a transforming year behind them and more updates are expected by the end of the year. We see the BET-inhibitor program as the most interesting from a partnering perspective and the prospects for a licensing deal are good. Further, an additional drug discovery collaboration deal has a good possibility of being realized. In this new Research Update Mathias Spinnars is summing up the fiscal year 2016/17, what lies ahead and the valuation of the company. Continue reading at: https://goo.gl/j6MkGi
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se